ANEUVO, a platform and therapy development company, has initiated a clinical study of the ExaStim® TSS system, a wirelessly-controlled neuromodulation system designed to deliver transcutaneous spinal cord stimulation (TSS).
ANEUVO Launches US Study of ExaStim, a Non-invasive Spinal Neuromodulation System to Evaluate its Safety and Effectiveness for Paralysis due to Spinal Cord Injury
Los Angeles, CA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Los Angeles. – February 2, 2023 – Today, ANEUVO, a platform and therapy development company, has initiated a clinical study of the ExaStim® TSS system, a wirelessly-controlled neuromodulation system designed to deliver transcutaneous spinal cord stimulation (TSS). The ASPIRE™ (Assessing non-invasive spinal Stimulation and PT/OT for motor Improvement Response with ExaStim®) study will evaluate the safety and effectiveness of ExaStim in combination with traditional rehabilitation therapy as an adjunct therapy for individuals living with upper extremity paralysis due to spinal cord injury (SCI).
